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Objective: The purposes of this study were to (1) evaluate correlations among platelet, 
leukocyte, growth factor, and cytokine concentrations in canine platelet-rich plasmas 
(PRPs) produced from five different canine PRP-concentrating systems and (2) compare 
the effects of different activation protocols on platelet activation and growth factor release 
from one of these PRPs.
Methods: PRP was made using blood from 15 dogs and each of 5 different PRP 
systems in a cross-over design. Complete blood counts were performed to quantify 
platelet and leukocyte concentrations. PRPs were activated, or not, according to 
manufacturer instructions, and transforming growth factor-β1 (TGF-β1), platelet-derived 
growth factor-BB (PDGF-BB), vascular endothelial growth factor, and tumor necrosis 
factor-alpha (TNF-α) were quantified. Differences among platelet, leukocyte, and growth 
factor concentration were compared among the different systems. Correlations between 
platelet and anabolic growth factor concentrations were assessed. Subsequently, PRP 
was made from 12 additional dogs using one of the devices. Each PRP was divided 
into three aliquots that were activated with calcium chloride (CaCl2), human γ-thrombin 
(HGT), or not activated. Expression of CD62P and platelet-bound fibrinogen (CAP1) was 
quantified for each activation group. Concentrations of TGF-β1, PDGF-BB, and TNF-
α were also quantified for each activation group and a fourth group that was frozen/
thawed. Differences among activation groups were assessed by a Friedman test.
results: There were statistically significant differences among the PRPs made with 
difference devices with regard to platelet, leukocyte, TGF-β1, and PDGF-BB concentra-
tions (p < 0.0001). There were weak to moderate correlations (R2 = 0.07–0.58) between 
platelet and anabolic growth factor concentrations but it appeared that activation had a 
greater effect on growth factor concentration than did cellular composition. Intentional 
platelet activation significantly increased CD62P and CAP1 expression as well as TGF-
β1 and PDGF-BB concentrations in the one PRP in which all activation methods were 
assessed. Activation with HGT resulted in the greatest platelet activation, and CaCl2 and 
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inTrODUcTiOn
Human and equine platelet-rich plasmas (PRPs) that are prepared 
with different methodologies vary notably in their cellular com-
position, growth factor concentrations, and catabolic cytokine 
concentrations (1–4). Furthermore, it has been shown that the 
concentration of transforming growth factor-β1 (TGF-β1) and 
PDGF-AB is significantly and positively correlated with the plate-
let concentration in human and equine PRPs (4, 5). Conversely, 
the catabolic cytokines interleukin-1β (IL-1β) and TNF-α were 
positively correlated with the leukocyte concentration in two 
different human PRP preparations (4). Given that one of the pri-
mary mechanisms by which PRP may be beneficial is the delivery 
of anabolic growth factors, balanced by the delivery of catabolic 
cytokines, variability in the concentration of these proteins 
provided by different PRPs may be clinically relevant (6). Indeed, 
there is a growing body of evidence that variations in cellular 
composition, growth factor concentrations, and inflammatory 
cytokine concentrations in PRP can influence tissue metabolism 
both in vitro and in vivo (7–11).
As with human and equine PRPs, studies have demonstrated 
that canine PRPs also vary dramatically in their cellular composi-
tion (12–16). In addition, three studies provide data on growth 
factor concentration(s) in three different canine PRPs (13, 17, 18). 
However, just one PRP preparation was assessed in each study, 
cytokine concentrations were not quantified, and assessment of 
possible associations between cellular composition and growth 
factor concentrations in different canine PRPs has not been 
performed. As a result, there remains a need to quantify growth 
factor and cytokine concentrations in different canine PRPs in 
order to fully characterize these products and to assess the rela-
tive impact of cellular composition on growth factor and cytokine 
delivery.
In addition to cellular composition of PRPs, exogenous 
platelet activation protocols have been shown to affect growth 
factor and cytokine concentrations in PRPs and may, therefore, 
influence clinical efficacy (4, 17, 19–21). Studies comparing the 
effects of different platelet activation protocols on PRPs provide 
inconsistent results (22, 23). One study demonstrated greater 
cumulative growth factor elution from human PRP with collagen 
activation than with bovine thrombin activation (23). Conversely, 
another study reported greater growth factor release from human 
PRP with use of bovine thrombin when compared to collagen 
activation (22). In horses, exposure of PRP to ex vivo collagen or 
fibrin resulted in relatively small increases in the production of 
platelet-derived growth factor-BB (PDGF-BB) and TGF-β1 (21, 
24). Exposure of equine PRP to calcium chloride (CaCl2) and 
bovine thrombin produced more dramatic increases in PDGF-BB 
and TGF-β1 (21, 24).
With regard to canine PRPs, evaluation of calcium gluco-
nate activation, both with and without batroxobin, resulted in 
increased TGF-β1 concentrations in comparison to PRP that 
was not activated (19). More recently, CD62P expression was 
shown to be significantly increased in a leukocyte-rich canine 
PRP after activation with bovine thrombin (25). The CD62P 
protein, or P-selectin, is bound to the platelet alpha granule 
that remains internalized in platelets until platelets are acti-
vated and the alpha granule fuses with the platelet external 
membrane at which time the CD62P protein is externalized 
(26). Hence, increased CD62P expression is associated with 
activation and degranulation of platelets and is used as a 
marker of platelet activation (26, 27).
Although the aforementioned studies in dogs provide valu-
able information, there remain unanswered questions regarding 
activation of canine PRPs. Notably, it remains unclear what effect 
untested activation protocols, such as use of CaCl2, have on canine 
platelet activation. Further, only concentrations of TGF-β1 have 
been assessed and the effects of activation on concentrations of 
other growth factors and inflammatory cytokines have not been 
described. Last, comparison of calcium-based activation versus 
the use of thrombin has not been performed using canine PRP 
(21, 28, 29).
The purposes of this study were to (1) characterize the specific 
leukocyte populations in PRPs prepared using five different com-
mercially available systems; (2) characterize the anabolic growth 
factor and tumor necrosis factor-α (TNF-α) concentrations in 
those PRPs; (3) assess whether there was a correlation between the 
platelet or leukocyte concentrations of the PRPs and the growth 
factor and TNF-α concentrations; and (4) quantify the effects of 
using CaCl2 or human γ-thrombin (HGT) on platelet activation 
and growth factor concentrations in one of these canine PRPs. 
It was hypothesized that leukocyte concentrations would differ 
between PRPs. In addition, like previous studies using human 
and equine PRPs, it was hypothesized that there would be a 
moderate positive correlation (R2 >  0.5) between PRP platelet 
concentrations and PRP anabolic growth factor concentrations, 
as well as a moderate (R2 > 0.5) positive correlation between PRP 
leukocyte concentrations and TNF-α concentrations (4, 5). It was 
freeze/thaw elicited moderate increases in either growth factor release or CD62P and 
CAP1 expression.
conclusion: There are positive correlations between platelet and anabolic growth factor 
concentrations in canine PRPs. However, intentional platelet activation has a greater 
effect on growth factor delivery than platelet concentration. Thrombin provides more 
robust activation than CaCl2.
Keywords: canine, platelet-rich plasma, platelet activation, growth factors, cytokines
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hypothesized that all activation protocols would increase expres-
sion of CD62P and platelet-bound fibrinogen as well as concen-
trations of the anabolic growth factors TGF-β1 and PDGF-BB.
MaTerials anD MeThODs
This study was reviewed and approved by the University of Georgia 
Clinical Research Committee. Written and verbal description of 
the study was provided to owners prior to enrollment and all own-
ers signed written consent forms upon enrollment. No additional 
vulnerable populations were involved in this study.
animals
Fifteen healthy dogs weighing at least 15 kg and free of medical 
problems, other than osteoarthritis, as determined on the basis of 
medical history and results of a general physical examination and 
a complete blood count (CBC) were included. Results of the CBC 
had to be normal, including platelet counts greater than 125 × 103 
platelets/μL and less than 600 × 103 platelets/μL. No dogs received 
medication for the duration of the study period except for one 
dog that received the same daily dose of Carprofen throughout 
the study period.
PrP systems
Platelet-rich plasma was made using each of five different com-
mercially available systems in a 15-dog cross-over study (12). Five 
commercially available systems were used for PRP preparation: 
System 1 (Protec PRP, PulseVet, Alpharetta, GA, USA), System 
2 (MediVet PRP, MediVet Biologics, Nicholasville, KY, USA), 
System 3 (C-PET, Pall Corp, Port Washington, NY, USA), System 
4 (SmartPReP 2, Harvest Technologies, Plymouth, MA, USA), 
and System 5 (Angel, Arthrex Vet Systems, Naples, FL, USA). 
Four of these systems (Systems 1, 2, 4, and 5) involved use of 
centrifugation, and one (System 3) was a filtration-based system.
Blood acquisition
Blood was acquired from each dog on three occasions for PRP 
preparation with a minimum 4-week interval between succes-
sive phlebotomies. Dogs were sedated for all blood draws by 
IV administration of dexmedetomidine (Dexdomitor, Zoetis, 
Florham Park, NJ, USA) (0.005 mg/kg) and nalbuphine hydro-
chloride (Hospira, Lake Forest, IL, USA) (0.5  mg/kg). Sedated 
dogs were placed in lateral recumbency, and blood was collected 
from a jugular vein. PRP was prepared from each dog for all five 
systems. PRPs were made using Systems 1 and 2 associated with 
the first phlebotomy, with System 3 being used 4 weeks later, and 
with Systems 4 and 5, another 4 weeks later.
Blood was collected using an evacuated container needle and 
pressurized blood tubes containing anticoagulant (sodium citrate 
or ACD-A) that were provided by the manufacturer of Systems 
1 and 2. There was one blood tube in the kit for System 1, and 
it was filled in accordance with the manufacturer instructions. 
All four blood tubes included with System 2 were filled (total 
volume, 40  mL) even though manufacturer instructions stated 
that only two blood tubes (total volume, 20  mL) were needed 
when preparing PRP from canine blood. When collecting blood 
for use with Systems 3, 4, and 5, an 18-gauge, 45-mm catheter 
was inserted into a jugular vein, and blood was collected into a 
60-mL syringe containing ACD-A. Blood volumes of 55, 29, and 
44 mL were added to 5, 3, and 6 mL of ACD-A for systems 3, 4, 
and 5, respectively.
Blood tubes were manually inverted several times immediately 
following blood acquisition, and then placed on a blood tube 
rocker for 5 min to thoroughly mix the blood and anticoagulant. 
A 2-mL aliquot of anticoagulated whole blood was then moved 
to a tube coated with dry EDTA; that tube was maintained on a 
blood tube rocker to thoroughly mix the blood and EDTA. Tubes 
remained on the blood tube rocker until analysis.
PrP Preparation and sample Processing
Platelet-rich plasma was then made using the remaining anti-
coagulated whole blood and manufacturer-provided materials 
and centrifuges in accordance with manufacturer instructions, 
except with system 2 in which the manufacturer-provided 
centrifuge was not used. Rather, a swinging bucket centrifuge 
(Sorvall Legend X1R centrifuge with a TX-400 rotor, Thermo 
Fisher Scientific, Waltham, MA, USA) (radius 16.8 cm) was used 
with the acceleration and deceleration both set at 4 (scale of 1 to 
10). For System 5, the desired hematocrit in the PRP was selected 
as 2%. After the PRP was made, an aliquot (1–2 mL) of PRP was 
collected and placed in a blood tube coated with dry EDTA, 
mixed on a blood tube rocker, and a CBC was performed. Smears 
of both the whole blood and the PRP were made for differential 
analyses.
After aliquots of the PRP were taken for performance of the 
CBC and differentials, the remaining volume of the PRP sam-
ples were either activated (or not) according to manufacturer 
instructions. Specifically, both Systems 1 and 2 include a CaCl2 
activator. The authors were informed that this activator did not 
need to be used for System 1 (Adrian Lock, PulseVet, Alpharetta, 
GA, USA personal communication, May 2014). Therefore, no 
activation was performed for PRPs from Systems 1, 3, 4, and 5. 
These PRPs were centrifuged at 20,000 × g for 10 min to pellet 
any remaining cells in the PRP. The supernatant was isolated and 
frozen at −80°C for future growth factor and cytokine analysis 
as per manufacturer recommendations and as has been done 
with previous quantification of growth factor concentrations 
in equine PRP (21). The PRP from System 2 was activated by 
mixing the PRP (2 mL) with CaCl2 (Acticell, MediVet Biologics, 
Nicholasville, KY) to a final CaCl2 concentration of 24 mg/mL. 
After 30–45  min of mixing with the activator, the remaining 
liquid portion (releasate) was collected and frozen at −80°C for 
future growth factor and cytokine analysis.
Whole Blood and PrP analysis
All samples of whole blood and PRP were maintained on a blood 
tube rocker until performance of a CBC using an automated 
hematology analyzer (HemaTrue, Heska Corp, Loveland, CO, 
USA) that quantified the hematocrit, leukocyte, RBC, and plate-
let concentrations. All samples were analyzed 15–60  min after 
sample collection. A blood smear of each sample was prepared for 
a manual differential count and assessment of platelet clumping. 
One hundred leukocytes were counted for all samples except for 
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some of the leukocyte-poor PRPs in which the differential count 
was based upon assessment of 25 cells.
growth Factor and cytokine 
Quantification
The PRP supernatants or releasates (System 2) were thawed at 
room temperature and TGF-β1 (Mouse/Rat/Porcine/Canine 
TGF-β1 Quantikine ELISA Kit, R&D Systems, Minneapolis, 
MN, USA), PDGF-BB (Human PDGF-BB Immunoassay, 
R&D Systems, Minneapolis, MN, USA), vascular endothelial 
growth factor (VEGF; Canine VEGF Immunoassay, R&D 
Systems, Minneapolis, MN, USA), and TNF-α (Canine 
TNF-α Immunoassay, R&D System, Minneapolis, MN, USA) 
were quantified using enzyme-linked immunosorbent assays 
(ELISAs). With the exception of the PDGF-BB ELISA, these 
assays have been validated by the manufacturers for use with 
canine plasma samples. Further, all of the ELISAs, including the 
PDGF-BB assay, have been shown to meet industry accepted 
standards of both intra and inter-assay precision with ACD-A 
anticoagulated canine plasma samples specifically (30). Samples 
were run in duplicate, and all samples were assessed on the 
same day (simultaneously) for a given growth factor or TNF-α. 
Manufacturer instructions were followed including all instruc-
tions regarding sample acid-activation for the TGF-β1 ELISA. 
Following manufacturer instructions, samples were diluted 60-, 
20-, and 2-fold for TGF-β1, PDGF-BB, and VEGF assays, respec-
tively. Samples for the TNF-α assay were run without dilution as 
instructed by the manufacturer. The PDGF-BB ELISA is a human 
ELISA kit that contains a human recombinant standard. For this 
study, a canine recombinant PDGF-BB standard (PDGF-BB 
Canine Recombinant Protein, Genorise, Glen Mills, PA, USA) 
was used (30). All sample concentrations were assessed using 
a four-parameter logistic equation generated using statistical 
software (GraphPad, Prism 6, La Jolla, CA, USA).
Data analysis
Distribution of the platelet, leukocyte, growth factor, and 
cytokine concentrations were assessed for normality using 
histograms, probability plots, and multiple tests for normality 
including a Shapiro–Wilk test (SAS version 9.4, Cary, NC, 
USA). The platelet and total leukocyte data were adequately 
normal to justify comparison among PRP systems using a linear 
mixed effects model (SAS version 9.4, Cary, NC, USA). The full 
model included a fixed factor for the system and a random 
intercept for each dog. Pair-wise comparisons were made using 
a Tukey’s test.
Data for TGF-β1 and PDGF-BB concentrations were not 
normally distributed so differences among PRP preparations 
using different systems were compared using a non-parametric 
Friedman test (SAS version 9.4, Cary, NC, USA). When signifi-
cant, multiple comparisons were performed using Conover’s test 
[R (R Core Team); http://www.R-project.org/]. A Bonferroni 
correction was used to adjust for multiple comparisons.
Correlation between platelet concentration and TGF-β1 con-
centration was assessed for those PRPs that were not activated 
(Systems 1, 3, 4, 5). Correlations between platelet concentration 
and both TGF-β1 and PDGF-BB concentrations were assessed 
for the PRP releasates from System 2 that had been activated. All 
correlations were assessed using a Pearson’s test.
assessment of Platelet activation
Animals
In order to compare the effects of different activation protocols 
on canine PRP, blood was collected from an additional 12 healthy 
dogs that were not receiving any medications other than monthly 
paraciticides. Dogs were required to weigh at least 15 kg.
Blood Acquisition
Fresh whole blood (52.8  mL) was acquired from each dog 
without sedation. Blood was obtained from a jugular vein using 
a 19-gauge butterfly catheter, and was collected into syringes 
pre-loaded with ACD-A such that all blood was anticoagulated 
in a 1:7 ratio of ACD-A to whole blood. Syringes were placed 
on a platform rocker on a gentle setting for 5 min to thoroughly 
mix the blood and ACD-A prior to PRP preparation. For each 
dog, 1  mL of anticoagulated whole blood was analyzed using 
an automated hematology analyzer (HemaTrue, Heska Corp, 
Loveland, CO, USA) for a CBC. For nine dogs, the prothrombin 
time, activated partial thromboplastin time, and fibrinogen val-
ues were also quantified, it was done on citrated blood, collected 
separately.
Plasma Preparation
Fifty milliliters of the anticoagulated whole blood were pro-
cessed using a commercially available device (Angel, Arthrex 
Vet Systems, Naples, FL, USA; System 5) to produce PRP. PRP 
was created using the “manual” setting in which the user visually 
differentiates and manually distributes the resultant product into 
separate PRP, platelet-poor plasma, and red blood cell fractions. 
Platelet and leukocyte counts were performed on all PRP samples 
using the same hematology analyzer (HemaTrue, Heska Corp, 
Loveland, CO, USA).
Sample Handling and Activation
Immediately after preparation, the PRP samples were divided; 
one portion of PRP was used for flow cytometry and the other 
portion was used for growth factor and TNF-α analysis.
Platelet Activation Status
For assessment of platelet activation, PRP was diluted to 5,000 
platelets/μL using flow cytometry buffer solution (10  mM 
HEPES, 137  mM NaCl, 4mM KCl, 0.5  mM MgCl, 0.5  mM 
Na2HPO4, 0.1% glucose, 0.1% bovine serum albumin, pH = 7.4) 
immediately following preparation of the PRP. After dilu-
tion, the samples were divided into three activation treatment 
groups. CaCl2  (Haemonetics, Braintree, MA, USA) was added 
to the first aliquot to a final concentration of 20 mM, and HGT 
(Haematologic Corp., South Burlington, VT, USA) was added to 
the second aliquot to a concentration of 20 nM. Ten microliters 
of flow cytometry buffer solution were added to the third treat-
ment group to serve as the unactivated control. Five microliters of 
Gly–Pro–Arg–Pro-NH2 (Sigma Corp, St. Louis, MO, USA) were 
added to each aliquot to prevent fibrin polymerization. Samples 
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were gently mixed for 5 min at 23°C. After mixing, antibodies 
for CD61 (Clone Y2/51, Dako, Agilent Technologies, Santa Clara, 
CA; conjugated to allophycocyanin), CD62P (Clone AC1.2, 
Becton, Dickinson and Company, Franklin Lakes, NJ, USA; con-
jugated to phycoerythrin), or for platelet-bound fibrinogen using 
the Canine Activated Platelet-1 (CAP1)antibody (generously 
provided by M. Boudreaux) were added, followed by a 20-min 
incubation at 23°C in the dark. The CAP1 antibody was not con-
jugated to a fluorochrome, so a secondary antibody (IgG-FITC, 
Jackson Laboratories, West Grove, PA, USA) was added, followed 
by a second 20 min dark incubation. For both activated and unac-
tivated samples, a separate aliquot was prepared with only the 
secondary antibody to reflect non-specific binding of fluorescent 
secondary antibody and to establish a defined threshold of posi-
tivity. Following these incubations, all samples were fixed by the 
addition of 2% formalin prior to analysis using a flow cytometer 
(Becton-Dickinson LSRII, Franklin Lakes, NJ, USA). The initial 
gating logic was derived based on the forward and side scatter 
plot of events that expressed CD61. Subsequent analysis counted 
30,000 events in this platelet gate, and the median fluorescence 
intensity (MFI) was recorded from all samples for PE and FITC 
expression.
growth Factor and TnF-α concentrations
Samples to be used for growth factor and TNF-α analysis were 
further divided into four groups that were activated with CaCl2 
(final concentration of 20  mM), HGT (final concentration of 
20  nM), or only had flow cytometry buffer solution added to 
serve as an unactivated control and to match the unactivated 
samples that were assessed using flow cytometry. The fourth 
aliquot was frozen at −80°C after PRP preparation and without 
additional centrifugation so that the platelets could be ruptured, 
or activated, by the freezing process. After addition of CaCl2, 
HGT, or buffer solution, samples were gently mixed on a plat-
form rocker for 5 min at room temperature (22–24°C). Samples 
were subsequently centrifuged at 10,000 × g for 3 min to pellet 
any cellular contents and the supernatant was collected and 
frozen at −80°C until growth factor and cytokine concentra-
tions were quantified (21). Aliquots from the four treatment 
groups were subsequently thawed at room temperature and 
TGF-β1, PDGF-BB, and TNF-α concentrations were quantified 
using ELISAs as specified above (30). All samples were run in 
duplicate, and all samples were assessed on a single 96-well plate 
in a single assay.
statistical analysis
The distributions of TGF-β1 and PDGF-BB concentrations 
and the distributions of CD62P and CAP1 expression were not 
normally distributed based upon assessment of histograms, 
probability plots, and multiple tests for normality including a 
Shapiro–Wilk test (SAS version 9.4, Cary, NC, USA). Therefore, 
the effects of the different activation protocols on TGF-β1 and 
PDGF-BB concentrations and the expression of CD62P and CAP1 
were assessed using a Friedman test (SAS version 9.4, Cary, NC, 
USA). Pair-wise comparisons were made using Conover’s test [R 
(R Core Team); http://www.R-project.org/] with a Bonferroni 
correction.
resUlTs
The platelet concentration of the different PRPs varied sig-
nificantly (p < 0.0001) among the different preparation systems 
(Table 1). Tukey post hoc comparisons revealed that all systems 
were significantly different in direct system to system com-
parison (Table 1). The leukocyte concentrations of the different 
PRPs varied significantly (p < 0.0001) among the different PRP 
preparations (Table 1). Two systems produced a leukocyte-poor 
PRP with a leukocyte concentration just over 1 ×  103 cells/μL. 
Systems 3 and 4 notably increased leukocytes in comparison to 
the whole blood samples and system 5 had a neutral effect on 
leukocyte concentration in comparison to the whole blood (31). 
There were significant differences for all pair-wise comparisons 
among the different systems for leukocyte concentration except 
that there was no significant difference in the leukocyte concen-
trations between Systems 1 and 2. The percentage of leukocytes in 
the PRPs that were neutrophils for those systems with a notable 
leukocyte concentration were 42% for System 3, 39.4% for System 
4, and 9.7% for System 5 (Table 1).
The anabolic growth factor concentrations of the different PRPs 
were based on PRPs from all 15 dogs for all systems except for System 
2 in which 13 samples were assessed. Two samples had been frozen 
immediately following PRP preparation without an extra centrifuga-
tion to separate the platelets from the plasma in the PRP. Freezing can 
rupture platelets causing a release and associated increase in growth 
factor concentration and so these two samples were excluded (3). In 
addition, sufficient sample for quantifying TNF-α was available for 
just five PRPs from System 5. Since this system produced the smallest 
volume of PRP there was insufficient sample with which to quantify 
all growth factors and TNF-α concentrations for all 15 PRP samples.
The TGF-β1 and PDGF-BB concentrations of the PRPs pre-
pared from different systems differed significantly (p < 0.0001; 
Table 2). Transforming growth factor-β1 (lower limit of quantifi-
cation 31.3 pg/mL) was present in measurable concentrations in 
all samples and was significantly higher in samples that had been 
activated by CaCl2 (System 2) in comparison to the PRP from all 
other systems based upon pair-wise comparisons (p < 0.0001). 
There were also significant differences (p <  0.001) among the 
other systems in which platelet activation had not been performed 
and are depicted in Table 2.
Platelet-derived growth factor-BB was detectable only in 
samples that had been activated by CaCl2 (System 2; lower limit 
of quantification 31.3 pg/mL). Accordingly, the concentration of 
PDGF-BB was statistically greater in the releasate from this system 
when compared to all other systems (p < 0.0001). The concentra-
tion of VEGF was below the lower limit of quantification (39.1 pg/
mL) for the assay in all samples. Similarly, the concentration of 
TNF-α was below the lower limit of quantification (7.8 pg/mL) 
for all samples except for three of the samples from System 1. As 
a result, no correlations between any cellular populations in the 
PRPs and VEGF or TNF-α were assessed.
A weak positive correlation was found between the platelet 
concentration of PRPs that were not activated and circulating 
TGF-β1 concentration (R2 =  0.07, p <  0.05). When only the 
PRP releasate from system 2 was assessed, there was a moder-
ate positive correlation between the platelet concentration and 
FigUre 1 | correlation of platelet and transforming growth factor-β1 
(TgF-β1) concentrations for activated platelet-rich plasmas (PrPs) 
from system 2 (R2 = 0.40; p < 0.05).
TaBle 2 | Median (range) growth factor and cytokine concentrations  
(pg/ml).
PrP-concentrating system















PDGF-BB 0 (0–0)a 3,072 
(737–
6,562)b
47 (0–270)a 0 (0–296)a 0 (0–57)a
TNF-α 0 (0–40.8) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
VEGF 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Statistical comparisons were made between the different platelet-rich plasma (PRP) 
systems for transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor-
BB concentrations. If two systems share a common superscript letter within a row they 
are not significantly different (p > 0.05).
TaBle 1 | Mean (±sD) platelet and total leukocyte concentrations.
Platelet-rich plasma-concentrating system
1 2 3 4 5
Platelets* 169,933 ± 74,460a 743,000 ± 301,719c 452,800 ± 185,747b 1,340,667 ± 285,520e 1,035,667 ± 514,614d
Leukocytes* 1,100 ± 600a 1,393 ± 1,128a 19,967 ± 4,936c 25,807 ± 6,993d 10,927 ± 4,894b
Neutrophils 0 (0–0.46) 0 (0–0.7) 7.3 (3.4–15.5) 8.0 (6.4–17.1) 0.8 (0–2.9)
Band neutr. 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0.8) 0 (0–0.2)
Monocytes 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1.5) 0 (0–0)
Lymphocytes 0.9 (0.4–1.8) 0.9 (0.3–3.5) 10.3 (5.0–14.9) 13.3 (5.6–23.9) 7.7 (2.9–13.9)
Eosinophils 0 (0–0.2) 0.05 (0–0.4) 0.8 (0–1.4) 2.2 (0–5.8) 0.6 (0–4.9)
Basophils 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0.2)
*Signifies statistical significant among the different systems (p < 0.0001).
If two systems share a common superscript letter within a row, then they are not significantly different (p > 0.05). Platelet and total leukocyte concentrations are reported as cells/μL. 
The median (and range) are reported for the leukocyte subpopulations (neutrophils, band neutrophils, monocytes, lymphocytes, eosinophils, and basophils) in cells/μL × 103.
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the concentration of TGF-β1 (R2 =  0.40, p <  0.05, Figure  1) 
and a stronger correlation between platelet concentration and 
PDGF-BB concentrations (R2 = 0.58, p < 0.05, Figure 2).
effects of Platelet activation
The mean (±SD) platelet concentration in the PRP (Angel, 
Arthrex Vet Systems, Naples, FL, USA) samples was 969 × 103/μL 
(±355 × 103/μL), with a 4.2 (±1.3)-fold mean increase in platelet 
concentration above the baseline whole blood sample, and with 
a mean leukocyte concentration of 7.24  ×  103 leukocytes/μL 
(±0.004  ×  103/μL). The prothrombin time, activated partial 
thromboplastin time, and fibrinogen values were within reference 
ranges for the nine dogs for which these values were quantified.
Based upon a Friedman test the activation treatment had a 
significant effect on CD62P MFI (p < 0.0001; Figure 3), CAP1 
MFI (p <  0.0001; Figure  4), TGF-β1 concentration (p <  0.01; 
Figure  5), and PDGF-BB concentration (p <  0.001; Figure  6). 
For each of these outcome variables, the degree of platelet activa-
tion, based upon either MFI or growth factor concentration, was 
numerically greatest with HGT activation, intermediate with 
CaCl2 activation or freeze/thaw, and lowest with the unactivated 
samples (Figures  3–6). With pair-wise comparisons using 
a Conover’s test and Bonferroni correction, HGT activation 
resulted in significantly higher CD62P expression than CaCl2 
activation (p < 0.0001), and CaCl2 activation resulted in signifi-
cantly greater CD62P expression than the unactivated samples 
(p < 0.0001, Figure 3). Treatment had a similar and significant 
effect on CAP1 MFI (p <  0.0001; Figure  4), and based upon 
pair-wise comparisons MFI with HGT was significantly greater 
than with CaCl2 activation (p <  0.0001) and MFI with CaCl2 
activation was significantly greater than the unactivated control 
(p < 0.0001; Figure 4).
Detectable concentrations of TGF-β1 and PDGF-BB were 
identified in multiple samples, while TNF-α was not detected in 
any of the samples. There were statistically significant differences 
among the activation groups for both TGF-β1 and PDGF-BB 
concentrations (p < 0.01 and p < 0.001, respectively; Figures 5 
and 6). The TGF-β1 concentration was significantly greater with 
HGT activation than with all other treatment groups including 
with a freeze/thaw (p < 0.05). TGF-β1 concentration with freeze/
thaw was greater than that with CaCl2 activation (p < 0.05) or 
the unactivated sample (p < 0.001). The TGF-β1 concentration 
was not statistically significantly different between the CaCl2 and 
unactivated control (p > 0.05; Figure 5). The PDGF-BB results 
were similar to the TGF-β1 results. The PDGF-BB concentration 
was greatest with HGT activation, intermediate with freeze/thaw 
FigUre 5 | Transforming growth factor-β1 (TgF-β1) concentration. 
HGT, human γ-thrombin; CaCl2, calcium chloride; Not Act, not activated. The 
middle line represents the median, the ends of the box are the 25th and 75th 
percentiles, and the whiskers are the minimum and maximum values. 
Activation treatment group had a significant effect on TGF-β1 concentration 
(p < 0.01). If two groups share a common letter they are not significantly 
different (p > 0.05).
FigUre 4 | Median fluorescence intensity (MFi) for caP1. HGT, human 
γ-thrombin; CaCl2, calcium chloride; Not Act, not activated. The data have 
been log transformed to reduce skew of the data for visualization of 
differences among the three groups. The middle line represents the median, 
the ends of the box are the 25th and 75th percentiles, and the whiskers are 
the minimum and maximum values. Activation treatment group had a 
significant effect on MFI (p < 0.0001) using a repeated measures analysis 
and each of the treatment groups was significantly different than the other 
treatment groups based upon pair-wise comparison.
FigUre 3 | Median fluorescence intensity (MFi) for cD62P. HGT, 
human γ-thrombin; CaCl2, calcium chloride; Not Act, not activated. The data 
have been log transformed to reduce skew of the data for visualization of 
differences among the three groups. The middle line represents the median, 
the ends of the box are the 25th and 75th percentiles, and the whiskers are 
the minimum and maximum values. Activation treatment group had a 
significant effect on MFI (p < 0.0001), and each of the treatment groups was 
significantly different than the other treatment groups based upon pair-wise 
comparison.
FigUre 2 | correlation of platelet and platelet-derived growth 
factor-BB (PDgF-BB) concentrations for activated platelet-rich 
plasma (PrPs) from system 2 (R2 = 0.58; p < 0.05).
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and CaCl2 activation and not significantly different between these 
two groups (p > 0.05), and significantly lower than either freeze/
thaw (p < 0.0001) or CaCl2 activation (p < 0.001; Figure 6) with 
the unactivated control.
DiscUssiOn
These data demonstrate substantial variability among the platelet, 
leukocyte, and growth factor concentrations of different canine 
PRPs. Variability in the leukocyte concentrations of different 
canine, equine, and human PRPs has been shown previously 
so these results were not unexpected (1, 4, 12, 16). In addition, 
the data from this study demonstrate that the specific leukocyte 
populations in the different PRPs also differed dramatically 
depending upon the method of PRP preparation. Specifically, 
PRP made with systems 3, 4, and 5, all had a notable leukocyte 
concentration. However, approximately 40% of the leukocytes 
in the PRPs made with Systems 3 and 4 were neutrophils, while 
approximately 10% of the leukocytes in the PRP from System 5 
were neutrophils and approximately 80% of the leukocytes in 
that PRP were lymphocytes. Similar results were identified with 
another study of canine PRPs in which neutrophils comprised 
a substantial proportion of the leukocytes in PRPs made using 
System 3 and 4 (16). In addition, that study found that one of the 
PRP preparation systems produced a PRP that had a substantial 
leukocyte population, few neutrophils, and consisted primarily of 
monocytes and lymphocytes (16). The similarity in data from this 
study and the previously published study regarding PRPs made 
from Systems 3 and 4 provides re-assuring evidence that these 
FigUre 6 | Platelet-derived growth factor-BB (PDgF-BB) 
concentration. HGT, human γ-thrombin; CaCl2, calcium chloride; Not Act, 
not activated. The middle line represents the median, the ends of the box are 
the 25th and 75th percentiles, and the whiskers are the minimum and 
maximum values. Activation treatment group had a significant effect on 
PDGF-BB concentration (p < 0.001). If two groups share a common letter 
they are not significantly different (p > 0.05).
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results specifically are repeatable (16). Furthermore, that both 
this study and previous study document production of a PRP in 
which the leukocyte population is largely devoid of neutrophils 
and comprised primarily of lymphocytes and monocytes is also 
re-assuring that such PRPs can be produced with canine blood 
(16). The mechanism by which System 5 from this study pro-
duced a PRP with a leukocyte content that consisted primarily 
of mononuclear cells, whereas Systems 3 and 4 produced PRPs 
containing a greater concentration of neutrophils, remains 
unclear. However, this finding is potentially pertinent as studies 
of human PRPs demonstrated significant positive correlations 
between neutrophil and macrophage concentrations and the 
inflammatory cytokines IL-1β and matrix metalloproteinase-9 
(4). Further, neutrophils have been hypothesized to impede 
wound healing (20). Conversely, the authors are not aware of 
any established association between lymphocytes and catabolic 
cytokine concentrations in PRPs.
As has been found with human PRPs, these data also demon-
strate positive correlations between platelet concentration in PRP 
and anabolic growth factor concentrations. However, the correla-
tion between platelet concentration and TGF-β1 was weak, and 
was non-existent for PDGF-BB, when assessing the PRPs that had 
not been activated. Conversely, the correlations between platelet 
concentration and TGF-β1 and PDGF-BB concentrations were 
moderate or strong for activated PRP samples. This difference is 
most likely explained by the intentional activation of these PRP 
samples. Although this could be perceived as a flaw in study 
design, and thus an unfair comparison among systems, all the 
samples in this study were handled as advised by the manufactur-
ers. Hence, the results are representative of the PRPs obtained 
in clinical practice when following manufacturer instructions. 
More importantly, these data suggest that platelet activation was 
more influential on anabolic growth factor concentration than 
the platelet concentration alone. In turn, it is relevant to assess 
whether the platelets in all PRPs are capable of activation and 
growth factor release and how platelets in different canine PRPs 
respond to different activators (endogenous or exogenous).
To this end, PRP samples were then made with one of these 
commercial systems using a new group of canine blood donors. 
These PRP samples were assessed for the effects of activation pro-
tocol on platelet activation and growth factor release. Importantly, 
the PRP preparation methodology did not result in platelet acti-
vation, indicated by low baseline CD62P expression or platelet-
bound fibrinogen in unactivated samples. Furthermore, growth 
factors and TNF-α concentrations were minimal or absent in the 
PRP samples that were not activated. Conversely, HGT provided 
a robust platelet activation as CD62P, platelet-bound fibrinogen, 
and TGF-β1 and PDGF-BB concentrations were greatest with 
HGT activation (Figures 3–6). These results are at least similar 
to one study with dog PRP demonstrating substantial CD62P 
upregulation with bovine thrombin activation (25).
Use of CaCl2 also resulted in platelet activation, albeit to lesser 
degree than HGT activation. There was greater platelet expression 
of CD62P and more platelet-binding of fibrinogen (CAP1) when 
samples were activated with CaCl2 when compared to unactivated 
samples (Figure  3). In addition, PDGF-BB concentrations in 
the PRP samples activated with CaCl2 were significantly greater 
than those in the unactivated samples. There was no significant 
difference between the CaCl2-activated samples and unactivated 
samples with regarding to TGF-β1 concentration in this study. 
These results are somewhat similar to a previous study that 
quantified TGF-β1 in canine PRP and found that activation with 
calcium gluconate increased TGF-β1 concentrations in compari-
son to unactivated controls (19). The studies are similar in that 
they both demonstrate positive effects of calcium activation on 
canine PRP, yet they differ with respect to a significant effect on 
TGF-β1 concentration specifically (19). We hypothesize that the 
difference in effect on TGF-β1 release is attributable to a Type 
II statistical error in this study, in part because of use of fewer 
dogs, non-normality of the TGF-β1 concentrations, and use of a 
non-parametric statistical test. The previously performed study 
used more dogs (16 rather than 12) and they concluded their data 
were normally distributed and performed a parametric test, thus 
likely providing greater statistical power (19).
A single freeze/thaw cycle similarly caused an increase in the 
concentration of both TGF-β1 and PDGF-BB when compared to 
aliquots that were not activated. The concentration of TGF-β1 was 
also greater with a single freeze/thaw than with CaCl2 activation. 
Freezing the PRP may have increased growth factor concentra-
tion by cold-induced platelet activation occurring during the 
freezing process (32). Alternatively, the increase in growth factor 
concentration was probably caused at least in part by rupture of 
the platelets and granules during freezing and thawing, allowing 
release of growth factors (3).
When considered together, these data demonstrate that 
platelet activation status has a profound impact on the release of 
anabolic growth factors from canine PRPs, more so than just the 
cellular composition of the PRP. A relevant question is whether 
activation of PRP should be performed when used clinically. 
Exogenous activation may not be necessary as exposure to col-
lagen, such as may occur in injured soft tissue structures, can also 
result in platelet activation (22, 23). Furthermore, although initial 
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growth factor release with equine and human PRPs tends to be 
less with collagen than thrombin or calcium in vitro, at least one 
study demonstrated greater cumulative in vitro TGF-β1 release 
with collagen exposure than thrombin (22–24). Therefore, injec-
tion of PRP that has not been exogenously activated may result 
in sustained release of growth factors from platelets as they are 
activated at the site of injury (23).
Although use of PRP that has not been exogenously activated 
may result in sustained activation in vivo, this is difficult to con-
firm and in vivo activation may not occur consistently (21). To 
ensure provision of the highest concentration of growth factors 
at the time of PRP administration, these data support the conclu-
sion that thrombin (HGT in this study) should be used to activate 
the canine PRPs evaluated in this study. However, the availability, 
cost, and potential reaction to a xenogenic protein should also 
be considered. Conversely, use of calcium (either chloride or 
gluconate) provides a more moderate activation, but does not 
involve administration of a xenogenic protein. Last, if one were 
to freeze the PRP (Angel, Arthrex Vet Systems, Naples, FL, USA), 
injection of the thawed solution would result in delivery of a 
solution containing TGF-β1 and PDGF-BB concentrations that 
are as great or greater than that obtained with CaCl2 activation 
(Figures 5 and 6). However, numerous studies demonstrate that 
freezing is detrimental to platelet morphology, function, and 
growth factor release (33–35). As a result, platelets in previously 
frozen PRP are unlikely to continue synthesizing growth factors 
following thawing (33–35). Conversely, continued synthesis of 
platelet-derived proteins following activation, rather than just 
release of what growth factors are within the α-granules at the 
time of activation, has been shown in vitro (21, 36). Therefore, 
application of fresh PRP may allow continued production and 
release of growth factors in vivo for an extended period of time.
In summary, there are notable differences among the PRPs 
produced using these five different commercially available sys-
tems. Such differences include substantial variability in platelet, 
neutrophil, monocyte, and lymphocyte concentrations as well as 
significant differences in anabolic growth factor concentrations. 
As with human PRPs, there are positive correlations between 
platelet concentrations and TGF-β1 and PDGF-BB concentra-
tions in canine PRPs. However, comparison of growth factor 
concentrations among the different canine PRPs suggest that 
intentional exogenous activation has a greater effect than cellular 
composition on growth factor content and release in the PRP. 
This hypothesis is supported by the data comparing the effects 
of different activation protocols on CD62P expression, platelet 
binding of fibrinogen, and growth factor release using one canine 
PRP (Angel, Arthrex Vet Systems, Naples, FL, USA). The baseline 
platelet activation and growth factor concentrations were low 
with this PRP (in both parts of this study) when activation was 
not performed. However, activation with HGT caused a signifi-
cant increase in CD62P expression, platelet binding of fibrinogen, 
and release of TGF-β1 and PDGF-BB. A more moderate response 
was noted with use of CaCl2. A freeze/thaw of this PRP increased 
the concentration of both TGF-β1 and PDGF-BB in comparison 
to samples that were not activated and provided a higher concen-
tration of TGF-β1 than the CaCl2 activated samples. Ideally the 
assessment of intentional platelet activation would be performed 
with all canine PRP preparations to confirm that platelets in these 
different preparations are capable of activation and growth factor 
release. However, the data from this study and others suggest that 
most platelets in canine PRPs do respond to intentional activation 
(19, 25). A remaining clinical question is whether canine PRPs 
should be activated prior to use or whether activation occurs 
consistently in vivo.
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